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Strengths and limitations of this study
 ► Efficacy design: Strict eligibility criteria.
 ► Special emphasis on the patients’ perceptions of 
early recovery and their self- perceived ability to re-
turn to normal daily activities and work.
 ► Patient- partnership concerning the design of the 
study, the informational material and the burden of 
the trial from the patient’s perspective.
 ► Strict eligibility criteria possibly limit the generalis-
ability of the findings.
 ► Participants’ awareness of the group assignment 
(lack of blinding) increases the risk of performance 
bias.
AbStrACt
Introduction Although a great majority of patients 
with cervical radiculopathy syndrome can successfully 
be treated non- operatively, a considerable proportion 
experience persistent symptoms, severe enough to 
require neurosurgical intervention. During the past 
decade, cervical spine procedures have increasingly 
been performed on an outpatient basis and retrospective 
database analyses have shown this to be feasible and 
safe. However, there are no randomised controlled studies 
comparing outpatient care with inpatient care, particularly 
with emphasis on the patients’ perception of symptom 
relief and their ability to return to normal daily activities 
and work.
Methods and analysis This is a prospective, randomised, 
controlled, parallel group non- inferiority trial comparing 
the traditional hospital surveillance (inpatient, patients 
staying in the hospital for 1–3 nights after surgery) with 
outpatient care (discharge on the day of the surgery, 
usually within 6–8 hours after procedure) in patients who 
have undergone anterior cervical decompression and 
fusion procedure. To determine whether early discharge 
(outpatient care) is non- inferior to inpatient care, we will 
randomise 104 patients to these two groups and follow 
them for 6 months using the Neck Disability Index (NDI) 
as the primary outcome. We expect that early discharge 
is not significantly worse than the current care in terms 
of change in NDI. Non- inferiority will be declared if the 
mean improvement for outpatient care is no worse than 
the mean improvement for inpatient care, by a margin of 
17.3%. We hypothesise that a shorter hospital stay results 
in more rapid return to normal daily activities, shorter 
duration of sick leave and decreased secondary costs to 
healthcare system. Secondary outcomes in our study are 
arm pain and neck pain using the Numeric Rating Scale, 
operative success (Odom’s criteria), patient’s satisfaction 
to treatment, general quality of life (EQ- 5D- 5L), Work 
Ability Score, sickness absence days, return to previous 
leisure activities and complications.
Ethics and dissemination The study was approved by 
the institutional review board of the Helsinki and Uusimaa 
Hospital District on 6 June 2019 (1540/2019) and duly 
registered at  ClinicalTrials. gov. We will disseminate the 
findings of this study through peer- reviewed publications 
and conference presentations.
trial registration number NCT03979443.
IntroduCtIon
Cervical radiculopathy syndrome (CRS) or 
radiating arm pain caused by cervical nerve 
root irritation is a common complaint in 
otherwise healthy working- aged population 
with an annual incidence of approximately 
0.8 per 1000 inhabitants.1 Conservative treat-
ment is a viable alternative for the majority 
of patients with CRS, as their symptoms are 
periodic and improve with time. However, 
a considerable proportion of patients with 
CRS experience persisting symptoms severe 
enough to justify neurosurgical intervention. 
Anterior cervical decompression and fusion 
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(ACDF) operation, first described in 1950s by Cloward2 
and Smith- Robinson,3 has become the gold standard 
surgery for CRS.4 5 Originally, the ACDF procedure 
comprised of decompressing the nerve root followed by 
replacing the intervertebral disc by an autologous bone 
graft harvested from iliac crest to fuse the two adjacent 
vertebral bodies together. After the introduction of 
PEEK (Poly- Ethane- Ethene- Ketone) and titanium cages, 
autologous bone grafts are rarely used anymore to avoid 
morbidity related to the donor site. With the advent of 
minimally invasive surgical techniques, anterior cervical 
fusions can now be achieved with reduced tissue trauma, 
pain and blood loss.
In most countries, the contemporary postoperative 
clinical practice after ADCF is to keep the patients under 
surveillance overnight for immediate postoperative 
complications, typically cervical swelling, neck haema-
toma and postoperative bleeding in the epidural space. 
However, a number of recent retrospective database anal-
yses suggest that successful outpatient anterior cervical 
fusions can be done without an increased risk of compli-
cations.6–8 The surge of outpatient spine surgery, partic-
ularly in the USA, is also evident in the recent US- based 
clinical practice guidelines that advocate early discharge 
over inpatient care.9
To date, no randomised trial has compared outpa-
tient with inpatient care in patients who have under-
gone ACDF, particularly with a special emphasis on the 
patients’ immediate perceptions of the care given and 
their self- perceived ability to return to normal daily activ-
ities and work. We will conduct a pragmatic, randomised, 
non- inferiority trial comparing the traditional hospital 
surveillance (inpatient) with outpatient care (same day 
discharge, within 6–8 hours after procedure) for patients 
undergoing ACDF procedure. Non- inferiority of the new 
treatment (outpatient care) with respect to the reference 
treatment (inpatient care) is of interest on the premise 
that the new treatment has some other advantages, such 
as greater availability, faster recovery, reduced cost, less 
disabling, fewer adverse events (harms) or greater ease 
of administration.10 We hypothesise that with the current 
technique of performing ACDF, the outcome of patients 
in the outpatient care group is not worse than in the 
conventional postoperative strategy (inpatient care), 
exceeding the non- inferiority margin and with no signifi-
cantly increased risk of harms. We further hypothesise 
that patients treated on an outpatient basis would perceive 
themselves to be less disabled, subsequently encouraging 
them to return more quickly to their normal daily activ-
ities and work. This will be assessed as our secondary 
objective.
MAtErIAlS And MEthodS
overview of study design
We will start the FACADE as a single centre prospec-
tive randomised non- inferiority study with the primary 
objective to compare the traditional strategy of keeping 
patients under hospital surveillance overnight (inpatient 
group) to a strategy of early discharge (6–8 hours after 
procedure, outpatient group) in patients having under-
gone ACDF procedure. We are planning to expand the 
FACADE to two or three other university hospital centres 
in Finland if our recruitment is too slow. We hypothe-
sise that ACDF performed with current techniques will 
have comparable outcomes and no increased harms in 
the early discharge arm versus the conventional postop-
erative arm. Additionally, we hypothesise that patients 
treated on outpatient basis would perceive themselves as 
less disabled, subsequently encouraging them to return 
more quickly to their normal daily activities and work. 
This will be assessed as the secondary outcome.
Participant selection and recruiting process
We will screen all patients suffering from radiating arm 
pain referred to the department of neurosurgery at 
Helsinki University hospital for trial eligibility by the 
FACADE investigators. We will carry a standard clinical 
examination and MRI examination of the cervical spine. 
Patients with clinical and imaging findings consistent with 
a diagnosis of CRS and willing to undergo ACDF opera-
tion after being fully informed of the trial protocol and 
the benefits and potential harms of the surgery will be 
evaluated for eligibility.
Inclusion criteria
1. CRS unresponsive to non- operative treatment for 
at least 6 weeks or with severe progressive signs and 
symptoms of nerve root compression during conser-
vative treatment of shorter duration.
2. CRS is defined as pain, paresis or paresthesia in the 
corresponding nerve root distribution areas of C5, 
C6, C7 or C8.
3. Nerve root stenosis determined by MRI at treatment 
level correlating to CRS/symptoms.
4. Neck Disability Index (NDI) score ≥30 out of 100.
5. Age between 18 and 62 years.
6. No previous cervical operations.
7. Currently employed.
8. No comorbidities causing a need for a sick leave.
9. Provision of informed consent from the participant.
10. No contraindication for randomisation in postopera-
tive check (see exclusion criterias #8 and #10).
Exclusion criteria
1. MRI finding inconsistent with patient’s symptoms.
2. Diagnosed osteoporosis or permanent use of oral 
corticosteroids.
3. ACDF operation requiring plate or cage fixation with 
screws.
4. Active malignancy.
5. American Society of Anesthesiologists Physical Status 
Classification system (ASA) 4 and 5 patients (serious-
ly ill patients).
6. Pregnancy.
7. Abundant use of alcohol, drugs or narcotics.
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Table 1 Baseline characteristics
Outpatient Inpatient
Age (years), mean (SD)
Gender (female/male), n (%)
Dominant hand affected, n (%)
Work Ability Score (WAS)
Physically demanding job, n (%)
Ability to work normally irrespective of the 
symptoms? n (%)
Participation in leisure time activities irrespective of 
the symptoms? n (%)
Duration of symptoms (days), mean (SD)
Sick leave duration (days)
Prior treatments (Physiotherapy) n (%)
Non- steroidal anti- inflammatory drugs (NSAID) pain 
medication, n (%)
Opioid pain medication, n (%)
Neuropathic pain medication, n (%)
Euroqol health related quality of life assesment 
instrument (EQ- 5D- 5L), mean (SD)
Neck Disability Index (NDI) scores (0–100 NDI), 
mean (SD)
Neck pain at rest (0–10 NRS), mean (SD)
Arm pain at rest (0–10 NRS), mean (SD)
NRS, Numeric Rating Scale .
8. No possibility to be accompanied by an adult person 
over the first postoperative night after the surgery.
9. Insufficient Finnish language skills.
10. Distance to the closest hospital emergency more than 
60 min.
Informed consent
At the first appointment, we will provide the patients 
with detailed written and oral information of the trial 
and ask patients to sign a consent form. We will ensure 
that patients understand that the surgical procedure and 
the ensuing follow- up will be identical irrespective of 
study group allocation, and that the randomisation only 
occurs after the surgery. We will also inform the partici-
pants that participation in the study is entirely voluntary 
and any decision they make will not influence any future 
care. Participants will also be informed of their right to 
withdraw from the trial whenever they desire without the 
need to supply any reason for such decision, and in such 
cases their data acquired prior to withdrawal will be main-
tained in the study database and included in analysis to 
avoid bias. Patients who are eligible for the trial, but are 
not willing to undergo randomisation, will be asked to be 
included in a simultaneous, pragmatic follow- up cohort.
baseline assessment
Our baseline assessment includes documentation of the 
following characteristics: gender, birth date, education, 
current employment status, hand dominance, time from 
the onset of symptoms and recreational habits. We will 
also ask the participants to assess their physical workload 
(physically hard/demanding or not), their general health 
and usage of pain medication. Finally, we will also docu-
ment any prior conservative treatment (table 1).
ACdF operation and anaesthesia
A standard anaesthetic procedure will be used. Every 
patient will be given preoperatively 10 mg diazepam, 
1000 mg paracetamol and 90 mg etoricoxib. During the 
operation, anaesthesia is maintained with propofol infu-
sion with standard amount of fentanyl and rocuron.
FACADE neurosurgeons will carry out a standard ACDF 
operation as described previously.4 All FACADE neuro-
surgeons are members of the Finnish Neurosurgeons 
Association and have successfully completed at least 100 
ACDF operations over the past 5- year period. Interbody 
fusion is performed with a Poly- Ethane- Ethene- Ketone 
(PEEK) cage (Cespage, Easculap, BBrauns, Germany) 
and a confirmatory X- ray will be acquired at the end of 
the operation for ensuring the correct positioning of the 
cage. We will instruct the patients not to wear any type of 
collar postoperatively.
randomisation and concealment
After the surgery, we will take all patients to the recovery 
room for 2–3 hours for an immediate postoperative 
observation. When we have confirmed that the patients 
are fully conscious and cooperative, immediate postop-
erative complications are ruled out using a postoperative 
checklist, and patients’ final eligibility is confirmed. A 
member of the FACADE study group then carries out 
randomisation. The randomisation is a built- in property 
in the online electronic case report form (eCRF) system 
used in the trial. To minimise the risk of predicting the 
treatment assignment of the next eligible patient (to 
ensure concealment), we will perform randomisation 
with variable block size (block size known only to the 
statistician with no involvement in the clinical care of the 
participants in the trial).
Intervention
Outpatient (OutP) group
A ward nurse will evaluate all patients allocated to the 
outpatient group approximately 6–8 hours after surgery 
using a standardised FACADE discharge checklist. If 
the patient fulfils all discharge criteria, he/she will be 
instructed on how to deal with any concerns and will 
be discharged. At discharge, we will document the time 
elapsed from operation and provide the patients with 
prescriptions to manage postoperative pain and an 
absence from work medical certificate for the first post-
operative week.
Inpatient (InP) group
Patients allocated to inpatient care will be kept over-
night. A neurosurgeon on duty will assess the ‘read-
iness’ of the patient to be discharged using the 
FACADE discharge checklist. Identical to OutP group, 
at discharge we will document the time elapsed from 
operation and provide the patients with prescriptions 
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Table 2 The follow- up assessments and data collection timetable
Assessment BL SG 1 wk 2 wk 3 wk 1 mo 3 mo 6 mo
Informed consent X
Baseline form X
MRI X (X)
Randomisation   X
Adverse effects   X X (X) (X) X X X
WAS X X (X) (X) X X X
Return to work   X (X) (X) X X X
Return to previous activities   X (X) (X) X X X
ODOM   X (X) (X) X X X
Patients satisfaction to the treatment   X
Health resource utilisation   X (X) (X) X X X
Clinical examination X (X) (X)
NDI X X X X
NRS- AP X X (X) (X) X X X
NRS- NP X X (X) (X) X X X
EQ- 5D- 5L X X
() if required.
BL, baseline; mo, month postoperatively; NDI, Neck Disability Index; NRS- AP, Numeric Rating Scale Arm Pain; NRS- NP, Numeric Rating 
Scale Neck Pain; ODOM, Operative success; SG, surgery; WAS, Work Ability Score;wk, week postoperatively.
for postoperative pain management and an absence 
from work medical certificate for the first postoperative 
week.
Compliance to treatment allocation and possible crossover
If a patient allocated to OutP group does not consider 
herself/himself fit enough to be discharged or will not 
pass the discharge checklist (eg, due to severe nausea, 
neck swelling indicating a possible postoperative haema-
toma, insufficient relief of radiating upper extremity 
pain, severe neck pain, severe difficulties to swallow, a 
new paraesthesia or paresis on upper extremity or a new 
postoperative dysphonia), we will keep her/him at the 
ward for as long as deemed necessary. We will consider 
these patients crossovers.
Primary outcome measure
Neck Disability Index
Our primary outcome measure is the NDI (scale 0–100, 
with higher scores indicating worse outcomes and more 
symptoms), a validated, neck- specific, patient- reported 
measure of pain- related dysfunction11 12 We will use a vali-
dated Finnish version of the NDI.13 The primary assess-
ment time point is 6 months. We will also query the NDI 
at 1 and 3 months postoperatively, but these data are 
only intended to illustrate the trajectory of the treatment 
responses (table 2). We will consider 17.3% improvement 
from the baseline value as the minimal important differ-
ence (MID) for NDI.14
Secondary outcome measures
Neck and arm pain
We will ask the patients to estimate the intensity of their 
neck pain (NRS- NP) and arm pain (NRS- AP) using a 
standard internet- based Numeric Rating Scale (eNRS)15 
at baseline, and at 1 week, 1 month and 6 months after 
the surgery (table 2). We will use an 11- unit NRS scale 
ranging from 0 (no pain) to 10 (extreme pain). We will 
consider two points as the MID.15
Return to previous leisure activities
Before the operation, each patient will be asked to name 
the most important daily leisure activity they are not able 
to perform because of the disease. At each follow- up time 
point (table 2), participants will be asked to respond to 
the following question: ‘Have you been able to return to 
your leisure activity?’ (‘yes’ or ‘no’).
The single item Work Ability Score (WAS)
Patients will assess their ability to work according to single 
item 16WAS preoperatively/at baseline, at discharge 
after surgery, and 1 week, 1 month and 6 months after 
the surgery. The single- item WAS is an 11- point NRS in 
which a patient will assess his or her current work ability 
compared with the lifetime best, with a possible score of 
0 (‘completely unable to work’) to 10 (‘work ability at its 
best’).
The duration of sick leave
We will record the duration of sick leave, that is, the 
number of sickness absence days both before and after 
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the operation. The number of sickness absence days will 
be treated as a continuous variable.
other (ancillary) outcome measures
EQ-5D-5L
EQ- 5D- 5L is a standardised health- related quality of life 
instrument for assessing a patient’s general health and 
treatment outcome17 and details a patient’s self- assessed 
health profile. The scores can be converted into quality- 
adjusted life years (QALYs). An improvement of 0.24 
QALY will be considered clinically relevant.14
Patient satisfaction
We will elicit patients’ global assessment of satisfaction to 
the treatment at 6 months after operation with this ques-
tion: ‘If you were to choose again, would you choose an 
operative treatment?’ (‘yes’ or ‘no’).
Operative success
Operative success will be assessed at each follow- up time 
point (table 2) by the modified Odom’s criteria,18 in which 
the patient subjectively rates the perception of operative 
success from poor to excellent.19 We will consider the 
first and second categories (‘excellent’ and ‘good’) as a 
successful outcome of the operation and, conversely, last two 
categories (‘fair’ and ‘poor’) as an unsuccessful outcome.
Complications and adverse effects
Complications directly related to the interventions will be 
registered. Postoperative dysphonia and odynophagia will 
be assessed with 0 to 10 numerical rating scales NRS- DP 
(NRS- dysphonia) and NRS- OP (NRS- odynophagia) at 
each postoperative time point.20 21 NRS will be assessed 
on an 11- unit scale ranging from 0 (no dysphonia/odyno-
phagia) to 10 (extreme dysphonia/odynophagia).
The participants will also be encouraged to contact 
the hospital if any adverse effects occur. The patient’s 
contact with the healthcare system will be registered at 
every follow- up visit. Potential adverse effects (AEs) will 
be categorised as serious adverse effects (SAEs) or minor 
adverse effects (MAEs). Death, cardiovascular events, 
deep venous thrombosis, pulmonary embolism, systemic 
infection, postoperative neck haematoma, postopera-
tive monoplegia or tetraplegia, permanent dysphagia or 
dysphonia will be categorised as SAEs, and local infec-
tion, periodic dysphagia or dysphonia will be categorised 
as MAEs. The number and severity of complications and 
AEs will be assessed.
Follow-up
The full follow- up process is outlined in table 2. Our 
primary method for collecting follow- up information is 
an electronic questionnaire. A link to this questionnaire is 
sent via email to all patients at all follow- up time points. To 
assess the participants’ ability to return to everyday activi-
ties and return to work, we will also contact the participants 
by phone 1 week after the surgery. Special attention will be 
paid to patient’s self- perception of ability to return to work. 
If a patient is able to return to work, weekly follow- up will be 
terminated. If a patient does not feel able to return to work, 
the sick leave will be extended and a phone contact is sched-
uled on the next week. Weekly contacts will be continued 
for up to 3 weeks, if needed. In case of further need for sick 
leave beyond 1 month, a patient will be invited to an outpa-
tient follow- up visit. We collect data on healthcare resource 
utilisation at the 1- month, 3- month and 6- month follow- ups. 
In addition, we also encourage the patients to contact the 
FACADE study nurse if they encounter any problems that 
require medical attention at any time over the course of the 
follow- up.
Adherence and loss to follow-up
To safeguard against potential loss to follow- up, we will 
exclude individuals likely to pose suboptimal adherence 
to study follow- up, obtain verified contact information 
from each consented participant and remind the partic-
ipants of upcoming follow- up visits. All attempts will be 
made to make follow- up as convenient as possible for the 
patients. Participants are not required to visit the outpa-
tient clinic postoperatively. Only in case of suboptimal 
operative result or any other possible concern related 
to care, a patient will be offered an opportunity to be 
assessed at the outpatient clinic. Otherwise, follow- ups 
will be carried out using phone interviews and/or elec-
tronic questionnaires to be filled online. The follow- up 
schedule will not incur any costs to the participants. We 
will monitor the adherence to follow- up throughout the 
trial and send reminders to patients who fail to return 
follow- up questionnaires.
Missing items
We will use multiple imputation by chained equations 
to handle missing data for those statistical analyses that 
cannot handle occasional missing values.22 All variables 
to be included in the final analyses will be forced in 
the chained equation imputation model and possibly 
including auxiliary variables available in the dataset. The 
imputation algorithm, called fully conditional specifica-
tion, uses specific univariate model for each variable and, 
for each specific imputed dataset, iteratively imputes each 
variable with missing values and uses the imputed values 
in the imputation of other variables.
Sample size
The trial is primarily designed to ascertain whether outpa-
tient care is non- inferior to inpatient care, at 6 months 
after surgery, with NDI as the primary outcome. Only 
one primary analysis will be used to assess non- inferiority. 
The trial is powered to detect an MID in the NDI score 
between the two study groups. We set the MID for NDI 
(17.3%) as our margin of non- inferiority Δ based on 
the results by Parker et al.14 At the 6- month time point, 
non- inferiority can be claimed if the lower limit of the 
CI (based on difference in means in the NDI) is greater 
than the MID in the primary comparison. According to 
the CONSORT (Consolidated Standards of Reporting 
Trials) statement for non- inferiority and equivalence 
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trials,10 secondary outcomes can be managed using either 
a superiority or equivalence framework. In our trial, all 
secondary outcomes will be assessed with an equivalence 
hypothesis, but since our trial is not necessarily powered 
for these comparisons, and to avoid issues with multiplicity, 
we consider them exploratory or hypothesis- generating.
The sample size calculation is based on the primary 
outcome measure, NDI at 6 months after the surgery. 
The sample size is approximated using the equation 
(Equation 3.12 in Chow: Sample Size Calculations in 
Clinical Research, Third Edition CRC Press 2018) for 
non- inferiority test:
 
n1 = n2 and n2 =
(
zα+zβ
)2
σ2
(
1+ 1
)
(
ε−M)2  
Assuming no difference between treatment arms ( ε = 0 
in NDI score improvements), equal sample sizes (x=1, the 
SD 23%), a margin of non- inferiority Δ of 17.3%, one- 
sided 2.5% statistical significance criteria ( zα  = 1.96) and 
90% statistical power ( zβ  =1,28), we will need 44 patients 
per study group. Assuming a dropout rate of 15%, the 
group size increases to 52 patients. Accordingly, we set the 
recruitment target at 104 patients.
Statistical analysis
We will follow primarily intention- to- treat (ITT) principle 
in all our analyses. In the ITT analyses, the participants are 
included as randomised. Per- protocol and on- treatment 
analyses will also be used to avoid falsely claiming non- 
inferiority. Summary statistics will be given as mean (with 
SD) for continuous variables and as frequencies (with 
%) for categorical variables. Repeated measures mixed 
model (RMMM) analysis will be used for all continuous 
variables (both primary and secondary outcomes) where 
regression coefficients are allowed to differ between study 
subjects. Statistical significance is set to two- sided 5% level. 
The RMMM analysis allows the use of all available obser-
vations in the dataset, so the full dataset (dataset without 
multiple imputation) will be used in the analysis. Logistic 
regression will be used to assess categorical variables. R 
statistical software (R Core Team (2013). R: A language 
and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. http://www. R- 
project. org/) will be used for analyses.
The number and proportion of individuals eligible for 
and compliant with each follow- up will be documented. 
We will also carry out an analysis of the demographic and 
prognostic characteristics between the individuals who 
withdrew and those who remained in the study.
Safety considerations
To safeguard against possible complications related to 
postoperative haematoma, all patients are required to live 
within 60- min distance from a surgical emergency unit.
data management and sharing
All study data will be stored in an eCRF. On receipt of 
the data, the FACADE personnel, blinded to the group 
allocation, will make a visual check of the data and query 
all missing, implausible and inconsistent data. Hospital 
patient records will also be used to collect missing data 
and in interpreting inconsistent or implausible data. 
Participant ﬁles will be maintained in storage (both in 
electronic and paper format) at the coordinating centre 
for a period of 15 years after completion of the study.
Data generated by our research will be made available 
as soon as possible and will be available on reasonable 
request. Data access request will be reviewed by FACADE 
steering group. Requestors will be required to sign a Data 
Access Agreement.
blinded data interpretation
As previously,23 24 we will interpret the results of the trial 
according to a blinded data interpretation scheme.25 In 
brief, an independent statistician will provide the Writing 
Committee of the FACADE trial with blinded results 
from the analyses, with the groups labelled group A and 
group B. The Writing Committee will then interpret the 
results until a consensus is reached and agree in writing 
on all alternative interpretations of the findings. Once a 
consensus is reached, we will record the minutes of this 
meeting in a document coined ‘statement of interpre-
tation’, which is signed by all members of the Writing 
Committee. Only after reaching this common agree-
ment, the data manager and the independent statistician 
will break the randomisation code and the correct inter-
pretation is chosen. A manuscript will then be prepared 
and finalised for the publication of the results. Detailed 
minutes of blinded data interpretation meetings will be 
provided as a supplement to the trial manuscript.
Patient and public involvement
To achieve more patient- friendly design for our trial,26 we 
recruited six patient experts from the European Patients’ 
Academy on Therapeutic Innovation (EUPATI Finland, 
https:// fi. eupati. eu/). They were asked to review the 
consent form and the study questionnaires and to pilot 
the online eCRF before these were submitted to ethical 
institutional review board. Among piloting online eCRF, 
these experts were asked to assess the burden of the inter-
vention and time required to participate in the research, 
which both they estimated to be reasonable. After the 
FACADE study is completed. we will contemplate together 
with EUPATI Finland how to share the study results to the 
public.
data Safety and Monitoring Committee
The purpose of the Data Safety and Monitoring 
Committee (DSMC) is to advise the FACADE investiga-
tors regarding the continuing safety of the trial partici-
pants. The DSMC is comprised of two clinical experts 
(neurosurgeons) with prior trial experience and a clinical 
trial methodologist. All members are independent of the 
trial investigators and have neither financial nor scientific 
conflicts of interest with the trial.
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Ethics and dissemination
All patients included in FACADE will sign an ethics 
board–approved consent form that describes this study 
and provides sufficient information for patients to make 
an informed decision about their participation. All partic-
ipating centres must obtain ethics board approval from 
their institution for the study protocol, the consent form 
template, the CRFs and any additional protocol amend-
ments. Any protocol amendments will be communicated 
to the site investigators, the ethics board, trial participants 
and trial registries as necessary.
Information about study patients will be kept confiden-
tial and will be managed in accordance with the following 
rules: (1) all study- related information is stored securely 
at the clinical site, (2) all possible study patient informa-
tion in paper form is stored in locked file cabinets and is 
accessible only to study personnel, (3) all CRFs are iden-
tified only by a coded patient number, (4) all records that 
contain patient names, or other identifying information, 
are stored separately from the study records that are iden-
tified only by the coded patient number and (5) all local 
databases are password protected.
dISCuSSIon
The rationale for the FACADE trial includes (1) the 
growth in popularity of ACDF operations carried out as 
outpatient procedures over the last decade; (2) a lack 
of rigorous (RCT) evidence verifying the efficacy and 
safety of outpatient ACDF surgery; and (3) uncertainty 
regarding the possible effect of hospitalisation (vs early 
discharge) on the recovery of patients to previous leisure 
activity and return to work.
According to the CONSORT statement for non- 
inferiority trials,27 a non- inferiority trial seeks to deter-
mine whether a new treatment is not worse than a 
reference treatment by more than an acceptable amount. 
Because proof of exact equivalence is impossible, a 
prestated margin of non- inferiority (Δ) for the treat-
ment effect in a primary patient outcome is defined. 
Non- inferiority of the new treatment with respect to the 
reference treatment is of interest on the premise that the 
new treatment has some other advantage, such as greater 
availability, reduced cost, less invasiveness, fewer adverse 
effects (harms) or greater ease of administration. In this 
FACADE trial, we primarily set out to determine whether 
the outcome of outpatient group is non- inferior to the 
current standards of care (overnight stay) at 6 months 
postoperatively. Given that the hallmark symptom of this 
disease—and also the primary reason the patients seek 
for medical attention—is the disability caused by radi-
ating arm pain, we felt that the NDI is the most appro-
priate primary outcome for our trial. Although one can 
argue that rapid return to normal daily activities and work 
would be a better indication that a person has reached a 
stable health status, such contention may not be entirely 
accurate. Comprehensive data on sustainable return to 
work (RTW) show that a variety of personal and social 
factors have positive and negative influences on sustain-
able RTW.28 Obviously, the social environment and how 
it interrelates with personal factors like attitudes towards 
work and self- efficacy play a role alongside the alleviation 
of neck pain as predictors of RTW.
The appropriateness of the chosen margin of non- 
inferiority Δ is obviously a critical methodological issue 
regarding the validity of any non- inferiority trial. The 
CONSORT guidance states that it should be specified 
and preferably justified on clinical grounds, given that a 
too large margin of non- inferiority Δ will increase the risk 
of accepting a truly inferior treatment as non- inferior.27 
Given this, it could be argued that we should have picked 
a value smaller than the MID of the NDI as our margin 
of non- inferiority Δ, but as the MID defines the minimal 
important difference, we consider this decision justified.
Although the safety and particularly the long- term—
preferably sustained—success is of indisputable primary 
importance in any surgery, early discharge might pose 
advantages that currently remain unaddressed. In 
essence, while keeping patients hospitalised overnight 
after surgery might increase immediate postopera-
tive safety, it may come at the risk of overcautiousness, 
increased perceived disability, and increased morbidity/
disease toll. Given the existing evidence—primarily from 
registry- based studies—that suggests that ACDF surgery 
can be successfully performed as an outpatient procedure 
without increased safety concerns, we felt intrigued to test 
a hypothesis that early discharge encourages patients to 
return to their daily activities and work earlier than if they 
are hospitalised overnight. This hypothesis is the other 
primary study question of our prospective randomised 
trial.
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